Lawrence Faulkner

Dr. Lawrence Faulkner

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2020 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
MVMarta Verna
Marta Verna
ARAttilio Rovelli
Attilio Rovelli
RARajat Kumar Agarwal
Rajat Kumar Agarwal
RDRakesh Dhanya
Rakesh Dhanya
JWJacek Wachowiak
Jacek Wachowiak
Severe blood disorders and cancer are the leading cause of death and disability from noncommunicable diseases in the global pediatric population and a major financial burden. The most frequent of these conditions, namely sickle cell disease and severe thalassemia, are highly curable by blood or bone marrow transplantation (BMT) which can restore a normal health-related quality of life and be cost-effective. This position paper summarizes critical issues in extending global access to BMT based on ground experience in the start-up of several BMT units in middle-income countries (MICs) across South-East Asia and the Middle East where close to 700 allogeneic BMTs have been performed over a 10-year period. Basic requirements in terms of support systems, equipment, and consumables are summarized keeping in mind WHO’s model essential lists and recommendations. BMT unit setup and maintenance costs are summarized as well as those per transplant. Low-risk BMT is feasible and safe in MICs with outcomes comparable to high-income countries but at a fraction of the cost. This report might be of assistance to health care institutions in MICs interested in developing hematopoietic stem cell transplantation services and strengthening context appropriate tertiary care and higher medical education.

14 April 2020
Verified
Journal Article
Closed access
RDRakesh Dhanya
Rakesh Dhanya
ASAmit Sedai
Amit Sedai
KAKumari Ankita
Kumari Ankita
LPLalith Parmar
Lalith Parmar
RARajat Kumar Agarwal
Rajat Kumar Agarwal
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner

31 August 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CDCristina Diaz-De-Heredia
Cristina Diaz-De-Heredia
DBDorine Bresters
Dorine Bresters
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
AYAkif Yesilipek
Akif Yesilipek
BSBrigitte Strahm
Brigitte Strahm
SCSelim Corbacioglu
Selim Corbacioglu

1 November 2014 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
RARajat Kumar Agarwal
Rajat Kumar Agarwal
ASAmit Sedai
Amit Sedai
SDSunil Dhimal
Sunil Dhimal
KAKumari Ankita
Kumari Ankita
LCLuigi Clemente
Luigi Clemente
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
Jagriti Innovations developed a collaboration tool in partnership with the Cure2Children Foundation that has been used by health professionals in Italy, Pakistan, and India for the collaborative management of patients undergoing bone marrow transplantation (BMT) for thalassemia major since August 2008. This online open-access database covers data recording, analyzing, and reporting besides enabling knowledge exchange, telemedicine, capacity building, and quality assurance. As of February 2014, over 2400 patients have been registered and 112 BMTs have been performed with outcomes comparable to international standards, but at a fraction of the cost. This approach avoids medical emigration and contributes to local healthcare strengthening and competitiveness. This paper presents the experience and clinical outcomes associated with the use of this platform built using open-source tools and focusing on a locally pertinent tertiary care procedure—BMT.

1 August 1998 in Journal of Hematotherapy
Verified
Journal Article
Closed access
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
VTVeronica Tintori
Veronica Tintori
ATAngela Tamburini
Angela Tamburini
APAntonella Paoli
Antonella Paoli
AGAlberto Garaventa
Alberto Garaventa
GBGabriella Bernini
Gabriella Bernini
High-sensitivity immunocytochemistry was used to evaluate the relative frequency of neuroblastoma cells in bone marrow and peripheral blood in patients with neuroblastoma (NB). A total of 51 concomitant paired blood and marrow samples (102 total) from 35 patients with NB (age 4 months-31 years; stage 29 stage IV, 4 stage III, 2 stage IVS; 14 at diagnosis, 18 in relapse, 12 during treatment, and 7 off-therapy) were analyzed. Cytospins containing up to 10(6) cells each were prepared using the mononuclear cell (MNC) fraction. For immunocytologic staining, a primary mouse monoclonal anti-GD2 antibody (3F8), a secondary antimouse biotinylated antibody, and a streptavidin-alkaline phosphatase complex were used. A minimum of two cytospins containing a mean of 1.4 x 10(6) total MNCs was analyzed in addition to a negative and a positive control. No circulating tumor cells were detected when the concomitant marrow samples were negative or had 10,000 NB cells per 10(6) MNC (1%), the concomitant blood sample was positive for 9 of the 10. When both marrow and blood samples were positive (15 BM-PB pairs), NB cell frequency was significantly lower in blood, with a mean difference of 2.14 logs (median 2.22, range -0.16-4.8, standard error 0.38). In patients with NB, circulating tumor cell frequencies seem to be substantially lower than in concomitant marrow samples, with a mean difference of >2 logs.

1 August 2013 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
CUCornelio Uderzo
Cornelio Uderzo
GMGiuseppe Masera
Giuseppe Masera
Thalassemia major (TM) is the most frequent life-threatening noninfectious disease of childhood in the Middle East, South Asia, and Pacific Islands where it accounts for a significant proportion of childhood mortality, morbidity, and related health care expenses. In spite of major advances in supportive care during the last decade, many patients in low-income and middle-income countries still fare poorly because of high treatment costs and lack of accessible multidisciplinary teams, not to consider the risk of blood-borne infections, primarily hepatitis C. In selected low-risk patients with a compatible sibling, TM is highly curable by bone marrow transplantation (BMT), which also improves the quality of life and is cost-effective. Starting in 2008, the Cure2Children Foundation (C2C), an Italian Non-Governmental Organization, has supported a BMT network in Pakistan, which during 2012 was extended to India. The primary aim of this project was to assess feasibility, outcomes, and costs of matched-related BMT for thalassemia in young low-risk children using a well-established and tolerable strategy. A total of 100 matched-related BMTs have been performed to date by partner institutions within this C2C-supported network; in the 50 low-risk cases with TM, over 90% disease-free survival was obtained with procedure expenses within 10,000 USD/BMT, that is, an outcome comparable to that obtained in affluent countries but with a fraction of the expenses. This cure rate was also obtained in start-up BMT centers (1 in Pakistan and 1 in India) within a structured and intensive cooperation program. Twinning and other international cooperation strategies based on shared principles and a common vision may substantially facilitate access to BMT.